Injecting mRNA to instruct cells to make what looks like the protein a virus produces that would trigger a robust immune response. The mRNA disappears quickly, but the cooked product, the body’s reaction to it, lasts.
Companies are working on vaccines using mRNA technology. They encase the genetic mRNA instructions in lipid nanoparticles to protect them from the immune system.
Targeted Vaccines
Vaccines are a big business, but it can take years for lab breakthroughs to become market-ready products. That’s not the case with mRNA vaccines. Still, it’s just the start of a massive potential for these prophylactic and therapeutic vaccines to eradicate diseases.
mRNA-based vaccines first identify the antigen that will best prompt the immune system to fight the disease. Then, the mRNA is designed to contain the exact sequence of the protein, with a unique addition at the end that instructs cells to make it. The mRNA is encased in lipid nanoparticles that keep it intact until it enters target cells, producing the protein at high levels.
The innate immune system recognizes and produces antibodies that block or neutralize the antigen, thus protecting the body against the disease. And because mRNA-based vaccines encode specific proteins, they are far more effective than broadly-acting DNA vaccinations or chemically synthesized synthetic proteins.
mRNA-based vaccines also have great flexibility in production and application, allowing prophylactic and therapeutic vaccines for diseases as diverse as infectious diseases and cancer to be developed. But, despite this promise, mRNA vaccines must overcome several hurdles to advance into preclinical and phase 3 efficacy trials.
Disease Prevention
Since the first vaccine against smallpox in 1796, researchers have created virtually all new vaccines by injecting a “live” form of a virus to prompt an immune response. But mRNA technology holds promise for a faster, easier way to prevent disease by giving people mRNA that triggers their bodies to make the proteins needed to fend off viruses and bacteria.
mRNA vaccines teach cells to make a protein that functions as a key to enter the body, similar to what a virus or bacteria utilizes. This triggers the immune system to recognize and mount a defense, and the body can later recall this memory to ward off future infections of that pathogen.
mRNA’s flexibility means it can be used to develop vaccines against many infectious diseases and some cancers. Researchers can tweak mRNA for specific tumors or deliver it to maximize the immune response. For example, mRNA can be provided inside lipid nanoparticles or liposomes to encase and protect it as it travels to the body. This approach is likely to be employed in future cancer vaccine trials. mRNA’s relative simplicity also offers the potential to develop standard analytical testing strategies to support vaccine developers, manufacturers, and national control laboratories around the globe.
Immunotherapy
Immunotherapy mRNA technology is a groundbreaking approach to treating various diseases, including cancer and infectious diseases, by harnessing the body’s immune system. At the core of this technology is the use of messenger RNA (mRNA) to stimulate and guide the immune system’s response. One of the most prominent applications of mRNA technology is in cancer immunotherapy. Researchers develop mRNA vaccines or therapies that encode antigens associated with cancer cells.
The mRNA structure carries the coding sequence for a specific antigen, flanked by 5′ and 3′ UTRs and capped by a poly(A) tail, which is targeted to the endoplasmic reticulum (ER), where it is translated into protein. A single mRNA can also direct its self-amplification to generate many copies of the encoded antigen, producing high target protein levels in cells.
With its ability to stimulate potent immune responses, mRNA can deliver both cell- and humoral vaccines to protect against infectious diseases. This capability, along with mRNA’s speed of development and production, makes it an attractive alternative to traditional vaccines for new or emerging infectious diseases.
Personalized Medicine
Now, they are expanding the field to include prophylactic and therapeutic vaccines against countless infectious diseases and cancers.
The flexibility of mRNA to encode any protein, even those with complex sequences, makes it a promising vaccine platform. It also facilitates production in the same process used for recombinant proteins, which could lower costs and lead to faster development of vaccines.
Quantitative proteomics is a susceptible technique to measure protein expression levels in cells and tissues. It can be applied to identify disease biomarkers, screen drug efficacy, and develop new diagnostic tools and therapies.
The sensitivity of mass spectrometry can allow researchers to detect deficient abundance proteins, which are often overlooked by other techniques. It can also enable the detection of posttranslational modifications and other chemically induced changes in proteins that are important for their function.
Ultimately, personalized medicine is the ability to tailor medical diagnosis and treatment to an individual patient by considering genomic, transcriptomic, epigenetic, metabolic, and behavioral factors that affect their response to intervention. mRNA-based immunotherapy can serve as the foundation of this new paradigm by enabling rapid and cost-effective analysis of patients at the earliest stages of disease.